Journal of Clinical Psychopharmacology 2007: Vol 27 Index & Table of Contents

2007·8.1 MB·English

Journal of Clinical Psychopharmacology * Volume 27, Number 6, December 2007 Author Index
Deakin B, 575 Farré M, 625 Gonzalez-Pinto AM, 126 Hsieh E, 380
DeBrota DJ, 116, 121 Fazel S, 503 Goodwin G, 503 Huang M-C, 516, 523
Deckersbach T, 240 Feiger AD, 116 Gorenstein C, 314 Huang X, 329
Del Zompo M, 544 Feldman MD, 94 Gorman AR, 498 Hubbard R, 468
Delaveau P, 692 Fields HL, 112 Gorus E, 182 Huizenga JR, 221
Dennis MF, 193 Filho AS, 310 Gossop M, 188 Hulstijn W, 15
Dervaux A, 514 Firoozabadi A, 542 Gouin P, 212 Hummel T, 526
Desarkar P, 115,215, 305, 410 Fitzgerald PB, 488, 493 Goulia P, 235 Hung CH, 306
Desta Z, 28 Fleck J, 304 Graham J, 387 Husain N, 575
Detke MJ, 672 Fleischhacker WW, 403 Granath F, 723 Hynan LS, 498
Dettling M, 92 Flockhart D, 28 Grann M, 503 Hyphantis T, 235
Deuschle M, 602 Forbush KT, 143 Grant JE, 227
Deutschman, DA, 513 Franchini L, 99 Greenblatt DJ, 28
Deutschman, DH, 513 Francini S, 418, 539 Gregoriou S, 404
Di Nicola M, 519 Franke B, 338 Greist JH, 121, 534 Inoue T, 698
Diaz FJ, 22 Frankhauser P, 602 Grignon S, 90 Ivanova O, 365
Dickson RA, 62 Freitas MCS, 310 Grigoriadis S, 95 Iversen E, 357
Dingemanse J, 728 Freudenreich O, 240, 380 Grunze H, 104
Dirks AC, 313 Fulcheri M, 58 Gu J, 459 oi
Dittmann RW, 662 Furukawa TA, 352, 531 Guigueno S, 212
Dittmann S, 104 Guo W-B, 374 Jacobsen J, 259
Dobkin RD, 207 Guo X-F, 374 Jacobsen LK, 80
Dominguez S, 329 Gutiérrez M, 219 Jae YM, 400
G
Dong Q, 507 Jamal MM, 46
Dossenbach M, 329 Gaertner H-J, 730 Janicak PG, 550
H
Dowd SM, 550 Gallarda T, 237 Janiri L, 519
Downing ACM, 520 Galli R, 233 Habermeyer B, 396 Jefferson JW, 121, 534
Doyle R, 58 Gallinat J, 80, 156 Haghighi AB, 484, 542 Jeglic E, 534
Duggal HS, 89 Gallis T, 417 Haghshenas H, 484 Jentzsch C, 396
Dunayevich E, 252 Gallop RJ, 614 Haile CN, 246 Jerome L, 111
Dunlop BW, 614 Galvez-Andres A, 722 Haman K, 76 Joo YH, 712
Gambi F, 58 Hanusa BH, 322 Josiassen RC, 22
Gamel NN, 225 Harmatz JS, 28 Joslyn G, 112
Ganocy SJ, 412 Harnack D, 537 Juckel G, 555
Eap CB, 273 Garbutt JC, 507 He J-L, 667
Ebenbichler C, 403 Gardner D, 111 Heinz A, 537
K
Edlinger M, 403 Garfin SR, 135 Helland A, 308
Eerdekens M, 6 Garle M, 723 Hellen F, 156 Kahn D, 397
Egan G, 488 Garlow SJ, 614 Henderson DC, 240, 380 Kalfakis N, 407
Egberts ACG, 338 Garrabou G, 284 Henderson P, 321 Kallén B, 607
Egger C, 475 Gasse C, 259 Henna E, 314 Kalogeromitros D, 404
Elashoff RM, 99 Gastfriend DR, 507 Hermans MH, 52 Kalus P, 80
Elhaj O, 412 Gattaz WF, 126 Hermisson I, 104 Kampman KM, 344, 417
Engelhardt N, 116, 534 Gentil V, 314 Hertzberg MA, 193 Kanba S, 93
Eren S, 210 Gentile S, 35 Higuchi T, 93, 531 Kane JM, 1, 421
Etter J-F, 151 Gessa GL, 319, 544 Hill K, 677 Kantrowitz JT, 525
Evans A, 560 Ghanizadeh A, 528 Himmerich H, 662 Kapezinski F, 303
Evans DL, 614 Gibbs MA, 71 Hinze-Selch D, 662 Kapur S, 369, 575
Evans KR, 116 Gilmer WS, 304 Hirano S, 93 Karaffa M, 304
Evins AE, 240, 380 Glasper A, 188 Hirschowitz J, 614 Kashima H, 318, 401
Glick ID, 365 Hoekstra PJ, 52 Katoh C, 698
Goethe JW, 451 Hoepner CT, 295 Katzelnick DJ, 121, 534
FE
Goff DC, 240, 380, 582 Hoever P, 728 Kaye NS, 387
Fadda D, 544 Goforth HW, 216 Holsten F, 357 Keefe R, 582
Fagiolini A, 310 Gogus AK, 289 Holzer L, 325 Kelly DL, 400
Fahrer RD, 126 Gomes FA, 303 Hong KS, 712 Kemp DE, 304
Falasca K, 58 Gonopolsky Y, 620 Horowitz J, 380 Kennedy SH, 95
Farmen M, 520 Gonzalez-Parra S, 722 Houston JP, 392, 520 Keshavan MS, 703
07 © 2007 Lippincott Williams & Wilkins
Author Index Journal of Clinical Psychopharmacology * Volume 27, Number 6, December 2007
Khan S, 575 Lee J, 62 Matsuyama T, 698 Neuhaus AH, 92
Kim HC, 400 Leech N, 395 Matthews SC, 135 Newport DJ, 217
Kim JG, 400 Lennestal R, 607 Mavreas V, 235 Nich C, 160
Kim SG, 400 Levin DE, 550 May AL, 394 Nickel M, 475
Kim SH, 365 Levine J, 238 Mazzotti G, 126 Nicksch B, 710
Kinon BJ, 392 Levine SZ, 431 McIntyre RS, 95 Nicolai J, 221
Kirch W, 687 Levinson AJ, 493 McQuade RD, 171 Niederhofer H, 317
Kirkwood SC, 520 Levinson C, 160 Meadoff TM, 112 Nierenberg AA, 1, 421
Kitta M, 401 Licinio J, 99 Meertens JHJM, 414 Nilsson ME, 682
Klick-Davis A, 28 Liew E, 394 Melegari M, 571 Ninan PT, 614
Klier CM, 720 Ligtenberg JJM, 414 Mellacheruvu S, 206 Nizamie SH, 305
Kluge M, 662 Lim M, 712 Mellman TA, 85 Nomura K, 318, 401
Knopf U, 214 Lim P, 6 Mendhekar DN, 89 Norgaard M, 259
Kobak KA, 1, 116, 421, 534 Lin WK, 306 Menza MA, 207 Norton JW, 206
Koeb L, 273 Lindenmayer J-P, 714 Mergl R, 104
Kohno T, 698 Lindley SE, 677 Mets T, 182 O
Konarski JZ, 95 Lindstaedt M, 101 Micallef-Roll J, 692
Kontaxis T, 407 _ Lipsitz J, 534 Miewald JM, 703 O’Brien CP, 344
Kopitz J, 456 Lipsitz JD, 116 Minderaa RB, 52 O’Malley SS, 507
Koran LM, 225 Lisanby SH, 156 Mintz J, 46 Oberli F, 437
Kosten TA, 246 Litvan L, 725 Miro O, 284 Odlaug BL, 227
Kosten TR, 246 Liu C-Y, 543 Mitchell JM, 112 Oh MK, 400
Kotler M, 620 Liu-Seifert H, 252, 392 Modell JG, 121 Okuyama T, 531
Koyama T, 698 Lobo D, 314 Mogun H, 707 Olie JP, 237
Kramer M, 6 Lombardelli A, 233 Molde H, 357 Onal O, 224
Kranzler HR, 507 Loonen AJM, 423 Moleman 'P, 231 Onitsuka T, 93
Krauseneck T, 526 Lopez S, 284 Moller M, 108 Opgen-Rhein C, 92
Kraus T, 562 Lopez-Munoz F, 555 Monteban-Kooistra WE, 414 Oren DA, 171
Kress KR, 546 Lorenz RA, 524 Montrose DM, 703 Orler J-B, 437
Kruger S, 101 Lorenzini F, 418 Moore SD, 193 Oslin DW, 344
Krystal JH, 582 Lowengrub K, 620 Moreno RA, 314 Ossanna MJ, 672
Kryzhanovskaya L, 329 Lu M-L, 516 Morgan PT, 313 Ozdemir V, 46
Kubota Y, 727 Luo Y, 28 Morrens M, 15 Ozguven HD, 289
Kulkarni J, 488 Lutz UC, 730 Mortensen PB, 259
Kunz M, 303 Lynch KG, 344 Mosavinasab M, 67, 484 P
Kupfer DJ, 703 Moses-Kolko EL, 322
Kupsch A, 537 M Mossaheb N, 720 Padin JM, 722
Kuroki T, 93 Mouaffak F, 237 Padberg F, 526
Kushner S, 6 Macfadden W, 344 Mouly SJ, 437 Pallesen S, 357
Kusumi I, 698 Macher J-P, 279 Mowla A, 67, 484, 542 Pani A, 67
Kutcher SP, 111 Maciulis V, 6 Mueck-Weymann M, 687 Papageorgiou C, 404
Kuwilsky A, 214 Makris M, 404 Muehlbacher M, 475 Papageorgiou SG, 407
Kvale G, 357 Mallikaarjun S, 279 Mula M, 263 Pappas D, 235
Kwon JS, 712 Malvini L, 352 Mulder H, 338 Parasrampuria DA, 459
Kyomen HH, 408 Mancini DA, 95 Mulder PGH, 231 Park DY, 712
Mandelli L, 99 Miiller-Spahn F, 396 Parzer P, 546
L Mannelli P, 468 Mundt A, 537 Pastor A, 625
Manos G, 171 Mundt JC, 121, 534 Patel MX, 560
Laberg JC, 357 Marchand J, 90 Murray HW, 468 Patkar AA, 468
Lahuis BE, 52 Marcus RN, 171 Musin E, 620 Paton C, 198
Lai Y-C, 523 Marek GJ, 71 Mutlu E, 224 . Patrick A, 707
Lambert M, 182 Marek K, 71 Pedersen L, 259
Lamendola CA, 365 Marin H, 207 Peindl K, 468
N
Lang UE, 80, 156 Marras P, 319 Pelizza L, 571
Langohr K, 625 Martenyi F, 166 Nakajima S, 401 Perel JM, 322
Langsetmo HK, 110 Martin B, 415 Nakamura J, 93 Peritogiannis V, 235
Large C, 582 Martinotti G, 519 Nanry K, 387 Perloff ES, 28
Laszlo E, 151 Mathewson KA, 714 Neely RDG, 395 Perry P, 143
Lederbogen F, 602 Mathot RAA, 231 Neu P, 156 Perry PJ, 595 easAoseoeo e a e ee e
736
© 2007 Lippincott Williams & Wilkins
Journal of Clinical Psychopharmacology ¢ Volume 27, Number 6, December 2007 Author Index
Petersson A, 723 Rovner J, 126 Sim K, 394 Thinn SS, 394
Petrakis I, 160 Rowbotham MC, 112 Simpson G, 6 Thompson T, 387, 582
Pettinati HM, 344, 417 Ruggero CJ, 177 Simpson GM, 22 Tillet Y, 437
Pieraccini F, 23 P4a Ruigt GSF, 15 Sinha VK, 115, 215, 410 Timehin C, 560
Piez DA, 451 Sit DKY, 322 Tirado C, 344
Pinhard K, 396 S Skutle A, 357 Tohen M, 126
Pini S, 263 Slater MA, 135 Tomita M, 401
Plewes J, 682 Smeraldi E, 99 Torrens M, 625
Poling J, 160 Safarinejad MR, 444 Smith EH, 225 Toyomaki A, 698
Polizzotto NR, 233, 310 Sahoo S, 205 Solvason B, 225 Tramontina JF, 303
Pollack MH, 85 Sahraian A, 542 Solvason HB, 614 Tran Q-V, 639
Pollmacher T, 662 Saik S, 479 Sorensen HT, 259 Treuer T, 329
Polzer J, 682 Saiz-Ruiz J, 98 Spanoudaki N, 404 Troost PW, 52
Pons A, 284 Sajatovic M, 412 Sparkman T, 344 Tsunoda K, 401
Posternak MA, 177 Saka MC, 289 Spiegel D, 705 Tulleken JE, 414
Potter WZ, 116 Salazar DE, 279 Spigset O, 308 Turkcan A, 224
Praharaj SK, 725 Salgado-Pineda P, 692 Spitznas AL, 117
Prasad KM, 703 Sanz EJ, 106 Srihari VH, 525
U
Preshaw P, 437 Saria A, 720 - Sritharan A, 488
Preskorn SH, 28 Satta G, 544 Stauffer VL, 252 Uchida H, 318, 401
Pritchett YL, 672 Saylan M, 329 Stein MB, 85 Uehlinger C, 273
Scahill L, 52 Stephenson A, 479 Ungvari.GS, 667
Schacht A, 662 Stevenson R, 62 Urbano M, 705
Q
Schatz M, 475 Stiger T, 71 Usubiaga H, 590
Qalbani M, 529 Scheel M, 537 Stock E, 171
Quante A, 715 Scheffer H, 338 Stone TE, 94
V
Schloegelhofer M, 720 Stoppo M, 418, 539
R Schoedel KA, 459 Stowe ZN, 217 VA’ VISN I MIRECC Study
Schoenfeld DA, 240, 380 Straus JL, 304 Group, 160
Rabavilas A, 404 Schneeweiss S, 707 Strdhle A, 537 Valdagno M, 310
Rabinowitz J, 431 Schubert F, 80 Strowitzki T, 718 Vale S, 321
Rabovsky K, 396 Schuld A, 662 Stoylen IJ, 357 van den Broek WW, 231
Rado JT, 550 Schuller R, 459 Suh JJ, 417 van Engeland H, 52
Rai A, 705 Schweinfurth J, 206 Suppes T, 639 van Gerven J, 728
Ralevski E, 160 Secil Y, 210 Surguladze SA, 560 van Hyfte DMH, 311 2 3
Rapport DJ, 412 Seemueller F, 104 Suzuki T, 318, 401, 727 van Praag, HM, 423
Reaven GM, 365 Seemiiller F, 526 Swanson C, 94 Vari G, 229
Reed LJ, 188 Segraves RT, 62, 732 Swindle RW, 672 Varma A, 528
Reimers A, 110 Seibyl JP, 71 Szabo S, 46 Vatti G, 233
Reist C, 46 Seifert F, 80 Vecchiet J, 58
Remington G, 369 Seitz DP, 302 T Verkes RJ, 15
Remschmidt H, 710 Sellers EM, 459 Vesper J, 156
Rettenbacher M, 403 Serretti A, 99 Takeuchi 1, 318, 401 Vieta E, 104, 126
Ribeiro L, 99 Setoguchi S, 707 Tamaki N, 698 Vignoli T, 418, 539
Rickels K, 420, 614 Sevincok L, 107 Tamayo JM, 126 Vijapurkar U, 6
Rico-Villademoros F, 98 Shader RI, 327 Tamion F, 212 Vogel T, 526
Riedel M, 526 Shang Y, 71 Tan YL, 246 Volavka J, 582
Rigopoulos D, 404 Sharma A, 99 Taneja I, 76 Volkmer E, 526
Rigotti NA, 240, 380 Shaw MC, 143 Tauscher-Wisniewski S, 682 von Haebler D, 80
Roberts J, 387 Sheitman B, 479 Tavanti M, 233 von Knorring A-L, 326
Robertson D, 76 Shelton RC, 76 Taylor CC, 25 N&m
Robinson DS, 420 Shen Y, 246 Tek C, 525
Ww
Rodriguez RH, 722 Shiga T, 698 Teune LK, 221
Rogers JF, 71 Shim JC, 400 Thakur S, 99 Walker DJ, 62
Rosenbohm A, 315 Siepmann M, 687 Thase ME, 1, 421, 672 Wallace MS, 135
Rosenthal RN, 540 Siepmann T, 687 Theisen FM, 710 Wang PS, 707
Rossini D, 99 Sikich D, 116 Theoharides TC, 404 Wang WC, 62
Rossor AM, 395 Silber SA, 459 Thibaut F, 212 Watanabe K, 93, 318, 401
Rounsaville B, 160 Silvia RJ, 117 Thiblin I, 723 Webster EL, 582
737
© 2007 Lippincott Williams & Wilkins
Author Index Journal of Clinical Psychopharmacology * Volume 27, Number 6, December 2007
Wehmeier PM, 662 Wisner KL, 322 Y Zhai J-G, 374
Wehring H, 595 Wong M-L, 99 Zhang XY, 246
Yetimalar Y, 210
Weinstein B, 524 Woolley SB, 451 Zhao J-P, 374
Yokota K, 93
Wezenberg E, 15 Woznicki BA, 451 Zhou DF, 246
Young LT, 493
Whelan F, 99 Wu B, 306 Ziemssen T, 687
Youngstrom EA, 412
White RL, 112 Wu L-T, 468 Zijlstra JG, 414
Whitfield TH, 408 Wu R-R, 374 Zilberman ML, 314
Z
Whittingham T, 344 Zimbroff DL, 171
Whittington C, 198 Zanardi R, 99 Zimmerman M, 177
X
Wiatr G, 730 Zapata R, 126 Zink M, 214
Williams JBW, 534 Xiang Y-T, 667 Zermig G, 270 Zipursky RB, 369
Wilmink FW, 338 Xu J, 672 Zetin M, 295 Zisook S, 135
Winsberg B, 590 Xu Q, 246 Zeugmann S, 715 Zuardi AW, 310
Ad
738
© 2007 Lippincott Williams & Wilkins Jour
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
Subject Index
A Intravenous valproate treatment of Aggression
uncontrollable aggression: A case Intravenous valproate treatment
ABCBI1 genotypes
report (letter). Qalbani, Oct, 529 of uncontrollable aggression:
Increased (R)-methadone plasma
Lithium toxicity presenting as A case report (letter).) Qalbani,
concentrations by quetiapine in catatonia in an adolescent girl Oct, 529
cytochrome P450s and ABCB/
(letter). Desarkar, Aug, 410 Agitation
genotyped patients (brief report).
Repeated creatine kinase elevation Management of acute agitation in
Uehlinger, June, 273
under treatment with quetiapine, patients with bipolar disorder:
Activities of daily living (ADL)
clozapine, and aripiprazole in an Efficacy and safety of
Does serotonin augmentation have
adolescent (letter). Bachmann, intramuscular aripiprazole
any effect on cognition and Dec, 710 (brief report). Zimbroff,
activities of daily living in
Reply to comments by Drs April, 171
Alzheimer’s dementia? A
- Holzer and Baumann (reply). Akathisia, acute, see Acute akathisia
double-blind, placebo-controlled
von Knorring, June, 326 Alcohol dependence
clinical trial (brief report).
Selective serotonin reuptake Aripiprazole for relapse prevention
Mowla, Oct, 484
inhibitors in adolescent depression and craving in-alcohol-dependent
Acute akathisia still controversial (letter). Holzer, subjects: Results from a pilot study
Acute nocturnal akathisia induced by June, 325 (letter). Janiri, Oct, 519
clozapine (letter). Sahoo, April, 205 Adult suicidality Clozapine and amisulpride in
The effectiveness of intramuscular Fluoxetine and adult suicidality refractory schizophrenia and
biperiden in acute akathisia: A revisited: An updated meta-analysis alcohol dependence (letter).
double-blind, randomized, using expanded data sources from Dervaux, Oct, 514
placebo-controlled study placebo-controlled trials (brief Efficacy of extended-release
(brief report). Baskak, June, 289 report). Beasley Jr, Dec, 682 naltrexone in alcohol-dependent
Acute pancreatitis Adverse drug reaction patients who are abstinent before
Acute pancreatitis and diabetic Suicidality scores during treatment (brief report). O’ Malley,
ketoacidosis in a schizophrenic double-blind fluoxetine and Oct, 507
patient taking olanzapine (letter). desipramine treatment in Mexican GABAergic medications for treating
Kahn, Aug, 397 Americans (letter). Sharma, Feb, 99 alcohol dependence (letter).
Olanzapine-induced Adverse events (AEs) Caputo, Oct, 539
chylomicronemia presenting as Extrapyramidal adverse events Naltrexone and disulfiram in patients
acute pancreatitis (letter). Rossor, associated with atypical with alcohol dependence and
Aug, 395 antipsychotic treatment of bipolar current depression. Petrakis,
Selective serotonin reuptake disorder. Gentile, Feb, 35 April, 160
inhibitors and risk of acute Fluoxetine and adult suicidality Reply to Dr Caputo and colleagues
pancreatitis: A population-based revisited: An updated meta-analysis regarding “GABAergic medications
case-control study. Nergaard, using expanded data sources from: for treating alcohol dependence”
June, 259 placebo-controlled trials (brief (reply). Rosenthal, Oct, 540
Acute retention of urine report). Beasley Jr, Dec, 682 Use of alcohol during the treatment
Acute urinary retention associated Affective spectrum disorders of alcohol dependence with
with selective serotonin reuptake High-dose ziprasidone in y-hydroxybutyric acid: Risk of
inhibitors and ziprasidone (letter). treatment-resistant schizophrenia severe events are avoided by the
Chung, Oct, 517 and affective spectrum disorders: dose fractioning of the drug
Adolescents A case series (letter). Deutschman, (letter). Caputo, Aug, 418
Adjuvant levetiracetam in adolescent Oct, 513 Alcoholism
mania (letter). Desarkar, Aprii, 215 Aged, see also Elderly A double-blind, placebo-controlled
Duloxetine-induced ultrarapid Levetiracetam for manic behavior in pilot trial of quetiapine for the
cycling in an adolescent with hospitalized geriatric patients with treatment of type A and type B
bipolar depression (letter). dementia of the Alzheimer’s Type alcoholism. Kampman,
Desarkar, Feb, 115 (letter). Kyomen, Aug, 408 Aug, 344
ilkins Journal of Clinical Psychopharmacology * Volume 27, Number 6, December 2007 - 739
Subject Index Journal of Clinical Psychopharmacology ¢ Volume 27, Number 6, December 2007
Baclofen suppresses alcohol intake concomitant lithium (letter). concentration-controlled trial.
and craving for alcohol in a Bergemann, Oct, 546 Atkinson, April, 135
schizophrenic alcohol-dependent Transient hyperglycemia and Half a century of antidepressant
patient: A case report (letter). decreased glucose tolerance during drugs: On the clinical introduction
Agabio, June, 319 antipsychotic monotherapy with of monoamine oxidase inhibitors,
The Asp40 p-opioid receptor allele amisulpride (letter). Opgen-Rhein, tricyclics, and tetracyclics. Part I:
does not predict naltrexone Feb, 92 Monoamine oxidase inhibitors
treatment efficacy in heavy Amoxapine (guest editorial). Lopez-Munoz,
drinkers (letter). Mitchell, Amoxapine as an antipsychotic: Det; 595
Feb, 112 Comparative study versus Impact of study design on the
Alzheimer dementia, see Dementia of haloperidol. Chaudhry, Dec, 575 results of continuation studies of
the Alzheimer’s type Amygdala activation antidepressants (brief report).
Alzheimer’s disease (AD) Amygdala activation modulated by Zimmerman, April, 177
Does serotonin augmentation have levodopa during ‘emotional Pregabalin in patients with
any effect on cognition and recognition processing in healthy antidepressant treatment-resistant
activities of daily living -in volunteers: A double-blind, somatoform disorders: A case
Alzheimer’s dementia? A placebo-controlled study (brief series (letter). Harnack, Oct, 537
double-blind, placebo-controlled report). Delaveau, Dec, 692 Preventing postpartum complications
clinical trial (brief report). Anabolic androgenic steroids in the depressed pregnant women
Mowla, Oct, 484 Convulsions in users of anabolic (letter). Vale, June, 321
Exacerbation of myoclonus by androgenic steroids: Possible Relationship between quality of
memantine in a patient with explanations (letter). Petersson, reports of antidepressant
Alzheimer disease (letter). Dec, 723 randomized controlled trials and
Papageorgiou, Aug, 407 Analgesia treatment estimates: Systematic
The influence of galantamine on Efficacy of noradrenergic and review, meta-analysis, and
reaction time, attention processes, serotonergic antidepressants in meta-regression analysis. Cipriani,
and performance variability in chronic back pain: A preliminary Aug, 352
elderly Alzheimer patients (brief concentration-controlled trial. Relevance of exclusion criteria in
report). Gorus, April, 182 Atkinson, April, 135 antidepressant clinical trials: A
Amenorrhea Antieonvulsant drugs replication study (brief report).
Amenorrhea after sertraline The role of anticonvulsant drugs in Zetin, June, 295
introduction in an amisulpride- anxiety disorders: A critical review Reply to Drs Henderson and Vale
treated patient with undiagnosed of the evidence. Mula, June, 263 (reply). Wisner, June, 322
polycystic ovary disease (letter). Antidepressants, see also specific drugs Selective serotonin reuptake inhibitor
Peritogiannis, April, 235 Antidepressant therapy can improve discontinuation: Side effects and
American Society of Clinical adherence to antiretroviral other factors that influence
Psychopharmacology regimens among HIV-infected and medication adherence. Goethe,
Critique of the American Society of depressed patients (brief report). Oct, 451
Clinical Psychopharmacology’s Dalessandro, Feb, 58 Severe hypoglycemia following
model psychopharmacology Clomipramine-induced mood and venlafaxine intoxication: A case
curriculum, 4th edition (special perceived performance changes in report (letter). Meertens, Aug, 414
book review). Rado, Oct, 550 selected healthy individuals (letter). Sex differences in antidepressant
Amisulpride Gentil, June, 314 response in a Canadian primary-
. Amenorrhea after sertraline Delivery outcome in relation to care sample (letter). Grigoriadis, Al
introduction in an amisulpride- maternal use of some recently Feb, 95
treated patient with undiagnosed introduced antidepressants. Suicidality scores during
polycystic ovary disease (letter). Lennestal, Dec, 607 double-blind fluoxetine and
Peritogiannis, April, 235 Duloxetine-induced ultrarapid desipramine treatment in Mexican
Clozapine and amisulpride in cycling in an adolescent with Americans (letter). Sharma, Feb, 99
refractory schizophrenia and bipolar depression (letter). Suicides by violent means in
alcohol dependence (letter). Desarkar, Feb, 115 individuals taking SSRIs and other
Dervaux, Oct, 514 Efficacy of noradrenergic and antidepressants: A postmortem
Increase in plasma concentration of serotonergic antidepressants in study in Sweden, 1992-2004
amisulpride after addition of chronic back pain: A preliminary (brief report). Fazel, Oct, 503
740 © 2007 Lippincott Williams & Wilkins
Journal of Clinical Psychopharmacology ¢ Volume 27, Number 6, December 2007 Subject Index
Tadalafil for treatment of erectile Comparative study versus elderly VA population with
dysfunction in men on haloperidol. Chaudhry, Dec, 575 dementia between antipsychotic
antidepressants (brief report). Aripiprazole augmentation for and nonantipsychotic users.
Segraves, Feb, 62 treatment-resistant bipolar Barnett, Dec, 595
S
The effects of venlafaxine on depression: Sustained remission Discontinuation of risperidone,
autonomic functions in healthy after 36 months (letter). Kemp, olanzapine, and haloperidol in
volunteers (brief report). June, 304 first-episode psychosis (letter).
Siepmann, Dec, 687 Aripiprazole for relapse prevention Shim, Aug, 400
and craving in alcohol-dependent Extrapyramidal adverse events
Antidepressive pharmacotherapy
subjects: Results from a pilot study associated with atypical
Half a century of antidepressant
(letter). Janiri, Oct, 519 antipsychotic treatment of bipolar
drugs: On the clinical introduction
Aripiprazole improves metabolic disorder. Gentile, Feb, 35
of monoamine oxidase inhibitors,
adversity in olanzapine-treated Ghrelin and leptin response to oral
tricyclics, and tetracyclics. Part I:
schizophrenic patients (letter). glucose challenge among
Monoamine oxidase inhibitors
Chen, Oct, 516 antipsychotic drug—treated
(guest editorial). Lopez-Munoz,
Association of clozapine-induced children. Winsberg, Dec, 590
Dec, 555
weight gain with a polymorphism Late-onset neuroleptic malignant
% Antiepileptic drugs
in the leptin promoter region in syndrome in a patient using
| The role of anticonvulsant drugs in
patients with chronic schizophrenia olanzapine (letter). Kunz,
anxiety disorders: A critical review
in a Chinese population. Zhang, June, 303
of the evidence. Mula, June, 263
June, 246 Measuring movement disorders in
Antipsychotic medication Atypical antipsychotic drug—induced antipsychotic drug trials: The need
Association of acute symptoms and acute laryngeal dystonia: 2 case to define a new standard (guest
compliance attitude in noncompliant reports (letter). Mellacheruvu, editorial). Loonen, Oct, 423
patients with schizophrenia (letter). April, 206 Metabolic impact of switching
ii, Liu-Seifert, Aug, 392 Augmentation with a second antipsychotic therapy to
Clinical implications of antipsychotic in patients with aripiprazole after weight gain: A
antipsychotic-induced schizophrenia -who partially pilot study (brief report). Kim,
hyperprolactinemia in patients respond to clozapine: A meta- Aug, 365
with schizophrenia spectrum or analysis (brief report). Paton, Neuroleptic treatment effect on
bipolar spectrum disorders: Recent April, 198 mitochondrial electron transport
developments and current Clozapine and amisulpride in chain: Peripheral blood
perspectives. Byerly, Dec, 639 refractory schizophrenia and mononuclear cells analysis in
— Lamotrigine as add-on therapy in alcohol dependence (letter). psychotic patients (brief report).
d schizophrenia: Results of 2 Dervaux, Oct, 514 Casademont, June, 284
Clozapine and granulocyte Neuroreceptor gene polymorphisms
placebo-controlled trials. Goff,
colony-stimulating factor: Potential and olanzapine depressive symptom
Dec, 582
for long-term combination response in schizophrenia (letter).
| Ventricular arrhythmias and
treatment for clozapine-induced Houston, Oct, 520
" cerebrovascular events in elderly
neutropenia (letter). Mathewson, Olanzapine versus chlorpromazine in
x using conventional and atypical
Dec, 714 the treatment of schizophrenia: A
antipsychotic medications (letter).
Clozapine and olanzapine are pooled analysis of four 6-week,
ie Wang, Dec, 707
associated with food craving and randomized, open-label studies in
is. Antipsychotics, see also specific drugs binge eating: Results from a the Middle East and North Africa.
Acute urinary retention associated randomized double-blind study Dossenbach, Aug, 329
with selective serotonin reuptake (brief report). Kluge, Paliperidone extended-release tablets
inhibitors and ziprasidone (letter). Dec, 662 for prevention of symptom
ican Chung, Oct, 517 Comments on “Neurological soft recurrence'in patients with
b, 99 All-cause treatment discontinuation signs in schizophrenic patients schizophrenia: A randomized,
in schizophrenia during treatment treated with conventional and double-blind, placebo-controlled
other with olanzapine relative to other atypical antipsychotics” (letter). study. Kramer, Feb, 6
ni antipsychotics: An integrated Varma, Oct, 528 Prevalence and clinical
analysis. Beasley Jr, June, 252 Comparison of risk of characteristics of obsessive-
Amoxapine as an antipsychotic: cerebrovascular events in an compulsive symptoms associated
Vilkins © 2007 Lippincott Williams & Wilkins 741
Subject Index Journal of Clinical Psychopharmacology * Volume 27, Number 6, December 2007
with atypical antipsychotics Anxiety disorders clozapine, and aripiprazole in an
(letter). Lim, Dec, 712 An open-label trial of aripiprazole adolescent (letter). Bachmann,
Psychomotor and memory effects of augmentation for treatment- Dec, 710
haloperidol, olanzapine, and resistant generalized anxiety Resolution of haloperidol-induced
paroxetine in healthy subjects after disorder (letter). Menza, April, 207 hyperprolactinemia with
. short-term administration. Duloxetine in the treatment of social aripiprazole (letter). Lorenz,
Morrens, Feb, 15 anxiety disorder (letter). Crippa, Oct, 524
Quetiapine as treatment for delirium June, 310 Resolution of tardive dyskinesia after
during weaning from ventilation: The role of anticonvulsant drugs in addition of aripiprazole to
A case report (letter). Seemiiler, anxiety disorders: A critical review haloperidol depot (letter).
Oct, 526 of the evidence. Mula, June, 263 Kantrowitz, Oct, 525
Reversible delayed onset Aripiprazole Worsening of obsessive-compulsive
olanzapine-associated leukopenia An open-label trial of aripiprazole symptoms after treatment with
and neutropenia in a clozapine- augmentation for treatment- aripiprazole (letter). Mouaffak,
naive patient on concomitant depot resistant generalized anxiety April, 237
antipsychotic (letter). Thinn, disorder (letter). Menza, April, 207 Aripiprazole augmentation
Aug, 394 Aripiprazole and neuroleptic Aripiprazole augmentation for
Second-generation antipsychotic malignant syndrome (letter). treatment-resistant bipolar
exposure and metabolic-related Brunelle, April, 212_ depression: Sustained remission
disorders in patients with Aripiprazole augmentation of after 36 months (letter). Kemp,
schizophrenia: An observational tranylcypromine in treatment- June, 304
pharmacoepidemiology study from resistant major depression (letter).
Asp40 ,1-opioid receptor
1988 to 2002 (brief report). Reist, Goforth, April, 216
The Asp40 tL-opioid receptor allele
Feb, 46 Aripiprazole for relapse prevention
does not predict naltrexone
Sex difference in effects of typical and craving in qlcohol-dependent
treatment efficacy in heavy
and atypical antipsychotics on subjects: Results from a pilot study drinkers (letter). Mitchell,
glucose-insulin homeostasis and (letter). Janiri, Oct, 519
Feb, 112
lipid metabolism in first-episode Aripiprazole improves. metabolic
Atomoxetine
schizophrenia (brief report). Wu, adversity in olanzapine-treated
Combined overdose of atomoxetine
Aug, 374 schizophrenic patients (letter).
and methylphenidate in a
Significant elevations of prolactin Chen, Oct, 516
cytochrome P450 2D6 poor
levels in patients who shifted from Aripiprazole-induced obsessive-
metabolizer (letter). Reimers,
conventional depot antipsychotics compulsive disorder: A report
Feb, 110
to long-acting risperidone (letter). of 2 cases (letter). Desarkar,
First case of sialolithiasis associated
Lai, Oct, 523 June, 305
with atomoxetine (letter). Jerome,
Transient hyperglycemia and Atypical antipsychotic withdrawal
Feb, 111
decreased glucose tolerance during dyskinesia in 4 patients with mood
Autism
- antipsychotic monotherapy with disorders (letter). Urbano, Dec,
Glutamate antagonists seem to
amisulpride (letter). Opgen-Rhein, 705
Feb, 92 Management of acute agitation in be slightly effective in
Treatment of antipsychotic- patients with bipolar disorder: psychopharmacologic treatment
associated hyperglycemia with Efficacy and safety of of autism (letter). Niederhofer,
pioglitazone: A case series (letter). intramuscular aripiprazole June, 317
_ Edlinger, Aug, 403 (brief report). Zimbroff, Autonomic functions
Antiretroviral regimens April, 171 The effects of venlafaxine on
Antidepressant therapy can improve Metabolic impact of switching autonomic functions in healthy
adherence to antiretroviral antipsychotic therapy to aripiprazole volunteers (brief report).
regimens among HIV-infected and after weight gain: A pilot study (brief Siepmann; Dec, 687
depressed patients (brief report). report). Kim, Aug, 365 Autonomic nervous system
Dalessandro, Feb, 58 Pharmacokwmetics of aripiprazole and Effect of single-dose sertraline on the
Anxiety diseases concomitant carbamazepine (brief hypothalamus-pituitary-adrenal
Sexual disorders in subjects treated report). Citrome, June, 279 system, autonomic nervous system,
for mood and anxiety diseases Repeated creatine kinase elevation and platelet function. Ahrens,
(letter). Bossini, June, 310 under treatment with quetiapine, Dec, 602
742 © 2007 Lippincott Williams & Wilkins © z
Journal of Clinical Psychopharmacology * Volume 27, Number 6, December 2007 Subject Index
depression: Sustained remission in the leptin promoter region in
after 36 months (letter). Kemp, patients with chronic schizophrenia
Back pain
June, 304 in a Chinese population. Zhang,
Efficacy of noradrenergic and
Bipolar disorder June, 246
serotonergic antidepressants in
A 2-year, open-label pilot study of Metabolic impact of switching
chronic back pain: A preliminary
adjunctive chromium in patients antipsychotic therapy to
concentration-controlled trial.
with treatment-resistant aripiprazole after weight gain: A
Atkinson, April, 135
rapid-cycling bipolar disorder pilot study (brief report). Kim,
Baclofen
(letter). Amann, Feb, 104 Aug, 365
Baclofen suppresses alcohol intake
Weight gain during a double-blind
and craving for alcohol in a A randomized, placebo-controlled
multidosage clozapine study.
schizophrenic alcohol-dependent trial of citicoline add-on therapy in
de Leon, Feb, 22
patient: A case report (letter). outpatients with bipolar disorder
Agabio, June, 319 and cocaine dependence (brief Book review
Behavior report). Brown, Oct, 498 Critique of the American Society of
ane Levetiracetam for manic behavior Clinical implications of Clinical Psychopharmacology’s
in hospitalized geriatric patients antipsychotic-induced model psychopharmacology
with dementia of the Alzheimer’s “hyperprolactinemia in patients curriculum, 4th edition (special
Type (letter). Kyomen, Aug, 408 with schizophrenia spectrum or book review). Rado, Oct, 550
Behavioral improvement bipolar spectrum disorders: Recent Borderline personality disorder
Secondary bipolar disorder and developments and current (BPD)
diogenes syndrome in frontotem- perspectives. Byerly, Dec, 639 Megadose clonazepam dependence:
poral dementia: Behavioral Cortical inhibitory dysfunction in A case report (letter). Mowla,
improvement with quetiapine and bipolar disorder: A study using Oct, 542
sodium valproate (letter). transcranial magnetic stimulation Brain
Galvez-Andres, Dec, 722 (brief report). Levinson, Oct, 493 Effects of lithium on brain glucose
Benzodiazepines (BZDs) Effect of open-label lamotrigine as metabolism in healthy men (brief
An open-label trial of discontinuing monotherapy and adjunctive report). Kohno, Dec, 698
benzodiazepines in patients with therapy on the self-assessed Breast-feeding
cy chronic schizophrenia (letter). cognitive function scores of Oxcarbazepine treatment during
Nakajima, Aug, 401 patients with bipolar I disorder breast-feeding: A case report
Comparison of buprenorphine and (brief report). Kaye, Aug, 387 (letter). Lutz, Dec, 730
methadone in the treatment of Extrapyramidal adverse events Brief Psychiatric Rating Scale (BPRS)
opiate withdrawal: Possible associated with atypical Evidence-based guidelines for
advai.tages of buprenorphine antipsychotic treatment of bipolar interpretation of the Hamilton
for the treatment of opiate- disorder. Gentile, Feb, 35 rating scale for depression (letter).
benzodiazepine codependent Management of acute agitation in Furukawa, Oct, 531
patients? (brief report). Reed, patients with bipolar disorder: Buprenorphine
April, 188 Efficacy and safety of Comparison of buprenorphine and
Binge eating intramuscular aripiprazole methadone in the treatment of
(brief report). Zimbroff, April, 171
Clozapine and olanzapine are opiate withdrawal: Possible
associated with food craving and Secondary bipolar disorder and advantages of buprenorphine for
binge eating: Results from a diogenes syndrome in the treatment of opiate-
frontotemporal dementia:
randomized double-blind study benzodiazepine codependent
(brief report). Kluge, Dec, 662 Behavioral improvement with patients? (brief report). Reed,
quetiapine and sodium valproate
Biperiden April, 188
(letter). Galvez-Andres, Dec, 722
The effectiveness of intramuscular Bupropion
biperiden in acute akathisia: A Treatment adherence in individuals A 12-week double-blind,
double-blind, randomized, with rapid cycling bipolar disorder: placebo-controlled study of
n the placebo-controlled study (brief Results from a clinical-trial setting bupropion SR added to high-dose
1 report). Baskak, June, 289 (letter). Sajatovic, Aug, 412 dual nicotine replacement therapy
stem, Bipolar depression Body mass index (BMI) for smoking cessation or reduction
Aripiprazole augmentation for Association of clozapine-induced in schizophrenia (brief report).
treatment-resistant bipolar weight gain with a polymorphism Evins, Aug, 380 .
i |k i ns © 2007 Lippincott Williams & Wilkins 743
Subject Index Journal of Clinical Psychopharmacology * Volume 27, Number 6, December 2007
A placebo-controlled trial of China Clinical interviews
bupropion SR in the treatment of Association of clozapine-induced Rating the raters—who is the research
chronic posttraumatic stress weight gain with a polymorphism subject? (letter). Balon, Feb, 116
disorder (brief report). Becker, in the leptin promoter region in Reply to comments by Dr. Balon
April, 193 patients with chronic schizophrenia (reply). Engelhardt, Feb, 116
Bupropion in the treatment of in a Chinese population. Zhang, -Clinical relevance
pathological gambling: A June, 246 The crucial role of the therapeutic
randomized, double-blind, Hemoperfusion in the treatment of window in understanding the
placebo-controlled, flexible-dose acute clozapine intoxication clinical relevance of the poor
study. Black, April, 143 in China (brief report). He, versus the ultrarapid metabolizer
Perceptual disturbances associated Dec, 667 phenotypes in subjects taking
with low-dose bupropion Chlorpromazine drugs metabolized by CYP2D6 or
sustained-release treatment (letter). Olanzapine versus chlorpromazine in CYP2C19 (guest editorial).
Liu, Oct, 543 the treatment of schizophrenia: A de Leon, June, 241
pooled analysis of four 6-week,
Clinical trials
C randomized, open-label studies in A 12-week double-blind,
Canada the Middle East and North Africa. placebo-controlled study of
Sex differences in antidepressant Dossenbach, Aug, 329 bupropion SR added to high-dose
response in a Canadian primary- Chromium dual nicotine replacement therapy
care sample (letter). Grigoriadis, A 2-year, open-label pilot study of for smoking cessation or reduction
Feb, 95 adjunctive chromium in patients in schizophrenia (brief report).
Carbamazepine with treatment-resistant Evins, Aug, 380
Pharmacokinetics of aripiprazole rapid-cycling bipolar disorder A double-blind, placebo-controlled
and concomitant carbamazepine (letter). Amann, Feb, 104 pilot trial: of quetiapine for the
(brief report). Citrome, June, 279 Chylomicronemia ~° treatment of type A and type B
Cardiomyopathy Olanzapine-induced alcoholism. Kampman, Aug, 344
Early recognition of chylomicronemia presenting as A placebo-controlled trial of
clozapine-induced myocarditis acute pancreatitis (letter). Rossor, bupropion SR in the treatment of
(brief report). Annamraju, Oct, 479 Aug, 395 chronic posttraumatic stress disorder
Catatonia Cilostazol-augmented therapy (brief report). Becker, April, 193
Lithium toxicity presenting as Seven cases of late-life depression A randomized, double-blind,
catatonia in an adolescent girl treated with cilostazol-augmented placebo-controlled trial of
(letter). Desarkar, Aug, 410 therapy (letter). Baba, Dec, 727 augmentation topiramate for
Cerebrovascular events (CVEs) Citalopram chronic combat-related
Comparison of risk of Recurrent hyponatremia after posttraumatic stress disorder
cerebrovascular events in an substitution of citalopram with (brief report). Lindley,
elderly VA population with duloxetine (letter). Dirks, June, Dec, 677
dementia between antipsychotic 313 A randomized, -placebo-controlled
and nonantipsychotic users. Unfavorable smell with citalopram? trial of citicoline add-on therapy in
Barnett, Dec, 595 (letter). Ghanizadeh, Oct, 528 outpatients with bipolar disorder
Cervical dystonia Citicoline and cocaine dependence (brief
Cervical dystonia due to interaction A randomized, placebo-controlled report). Brown, Oct, 498
of valproic acid and quetiapine trial of citicoline add-on therapy in An independent meta-analysis using
(letter). Habermeyer, Aug, 396 outpatients with bipolar disorder summary data for clinical
Children and cocaine dependence (brief response, remission, and
Ghrelin and leptin response to oral report). Brown, Oct, 498 discontinuation for any reason
glucose challenge among Clinical Global Impression from the 6 pivotal phase III
antipsychotic drug—treated Improvement and Severity Scales randomized clinical trials of
children. Winsberg, Dec, 590 Bupropion fn the treatment of duloxetine in major depressive
Prolactin release in children treated pathological gambling: A disorder (letter). Ballesteros,
with risperidone: impact and role randomized, double-blind, April, 219
of CYP2D6 metabolism (brief placebo-controlled, flexible-dose Are the effects of rater training
report). Troost, Feb, 52 study. Black, April, 143 sustainable? Results from a
744 © 2007 Lippincott Williams & Wilkins